Wall Street Zen Upgrades Context Therapeutics (NASDAQ:CNTX) to “Hold”

Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

CNTX has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Finally, JonesTrading assumed coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Context Therapeutics Stock Performance

CNTX stock opened at $2.88 on Friday. The stock has a fifty day moving average of $2.35 and a 200-day moving average of $1.56. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $3.62. The company has a market capitalization of $264.71 million, a price-to-earnings ratio of -12.00 and a beta of 1.96.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently modified their holdings of CNTX. Millennium Management LLC purchased a new position in shares of Context Therapeutics during the 4th quarter valued at $3,824,000. Marshall Wace LLP increased its holdings in shares of Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after purchasing an additional 2,557,448 shares during the period. Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after buying an additional 188,202 shares in the last quarter. Vanguard Group Inc. boosted its stake in Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after buying an additional 134,449 shares during the period. Finally, Citadel Advisors LLC bought a new stake in Context Therapeutics during the third quarter valued at $100,000. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.